MedTrace Logo

Anti-Mullerian Hormone - At My Home

NCT04784325 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-06-22

No results posted yet for this study

Summary

The AMH\^2 (Anti-Mullerian Hormone - At My Home) study is a head-to-head-to-head validation study aiming to evaluate the concordance of AMH levels found in blood collected via three different routes: collected at-home using the TAP II device, drawn through standard venipuncture techniques, and collected with the ADx card, another at-home collection device widely available on the market for commercial use.

Conditions

  • Fertility Risk

Interventions

DIAGNOSTIC_TEST

Blood draw through TAP II

Two self-administered blood draws through TAP II device

DIAGNOSTIC_TEST

Blood draw through ADx cardT

One self-administered ADx card blood draw

DIAGNOSTIC_TEST

Blood draw through standard venipuncture

One phlebotomist-performed standard venipuncture

Sponsors & Collaborators

  • Turtle Health, Inc.

    lead INDUSTRY

Principal Investigators

  • Anatte E Karmon, Harvard University · Fertility Institute of Hawaii

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04784325 on ClinicalTrials.gov